Clinical trials: Carcinoma, Small Cell Lung
Small Cell Lung Cancer
Trial of BMS-986012 in Combination With Platinum and Etoposide
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
- Trial name
- NCT02815592
- Testing
- BMS-986012, Cisplatin, Etoposide
- Where
- 4 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Non Small Cell Lung Cancer
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients.
- Trial name
- COPE (NCT04258137)
- Testing
- Liquid biopsy
- Where
- 6 sites in France
- Volunteers
- 332 people
- Sponsor
- Institut Bergonié
Myelosuppression
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on…
- Trial name
- NCT06490081
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Carcinoma, Non-Small-Cell Lung, Mesothelioma
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer
- Trial name
- NCT03023319
- Testing
- Bosutinib, Pemetrexed
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nagla Abdel Karim
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors
Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Disitamab Vedotin combined therapy locally advanced or metastatic NSCLC Patients with HER2 Alterations.
- Conditions
- Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48, Disitamab Vedotin
- Trial name
- NCT05847764
- Testing
- RC48+Tislelizumab+carboplatin, RC48+Furmonertinib, 1L, RC48+Furmonertinib, 2L+
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Sun Yat-sen University
Lung Cancer (NSCLC)
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
This is a single arm, open-label exploratory study conducted in resectable stage II-IIIA NSCLC without EGFR/ALK mutations, aiming to investigate feasibility, safety and efficacy of Sugemalimab in perioperative contexts.
- Trial name
- NCT06987734
- Testing
- Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer (NSCLC)
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can…
- Trial name
- NCT05553834
- Testing
- Alirocumab and Cemiplimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Previous Treated Metastatic Non-small Cell Lung Cancer
Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients
To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer
- Trial name
- NCT01783834
- Testing
- Gefitinib, Pemetrexed
- Where
- South Korea
- Volunteers
- 95 people
- Sponsor
- Gachon University Gil Medical Center
Lung Cancer, Lung
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of…
- Conditions
- Lung Cancer, Lung, Lung Cancer (NSCLC), Metabolomics
- Trial name
- NCT06843707
- Testing
- Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.
- Where
- China
- Volunteers
- 2,500 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Non Small Cell Lung Cancer
Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer
The purpose of the study is to evaluate the response rate of patients with non small lung cancer to gemcitabine in combination with radiotherapy. The tolerability and safety of this combination will also be evaluated.
- Trial name
- NCT00192036
- Testing
- gemcitabine, cisplatin, radiation
- Where
- 8 sites in Belgium
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung, Depression
Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With Depression
This is a phase II, placebo-controlled, randomized, double-blinded clinical trial. Study objective is to assess the efficacy and safety of mirtazapine in advanced NSCLC patients with malignant tumor related depression.
- Trial name
- NCT02650544
- Testing
- Mirtazapine
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer
Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer
A phase II, multicenter, randomized, double-blind, placebo-controlled study was carried out. Patients were randomly assigned to the treatment (PC + pegylated endostatin) or the control group (PC+ placebo).
- Trial name
- NCT01527864
- Testing
- pegylated endostatin and Paclitaxel-Carboplatin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Non-small Cell Lung Cancer, EGFR Mutations
Understanding Mechanisms of Acquired Resistance to BIBW2992
In this research study we are looking to see how effective BIBW 2992 is at suppressing the development of the T790M mutation in non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT01074177
- Testing
- BIBW 2992
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Small Cell Lung Carcinoma
REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Primary lung cancer is one of the most common malignancies and causes of cancer-related death worldwide [Passiglia et al., 2019; Bade and Dela Cruz, 2020].
- Trial name
- ARAL (NCT06826677)
- Testing
- Durvalumab
- Where
- 11 sites in Italy
- Volunteers
- 71 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Squamous Non-Small Cell Lung
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel…
- Trial name
- IMpower130 (NCT02367781)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Nab-Paclitaxel
- Where
- 132 sites in United States, Belgium and 6 more
- Volunteers
- 723 people
- Sponsor
- Hoffmann-La Roche
NSCLC
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
This is a phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 and AK112 With or Without Chemotherapy for NSCLC patients.
- Trial name
- NCT05636267
- Testing
- AK119, AK112, Pemetrexed
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Akeso
EGFR Gene Mutation
Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC
YH25448 is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.
- Trial name
- NCT03046992
- Testing
- YH25448
- Where
- 16 sites in South Korea
- Volunteers
- 224 people
- Sponsor
- Yuhan Corporation
Carcinoma, Non-Small-Cell Lung
Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer
The main purpose of the study is to determine the activity of the weekly combination of docetaxel (Taxotere) and irinotecan in terms of response rate in subjects with advanced, previously untreated, non-small cell lung cancer.
- Trial name
- NCT00819728
- Testing
- Docetaxel, Irinotecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer
Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
60% of all malignant diseases occur in patients who are 65 years or older. For these patients, aggressive treatments are often not suitable due to reduced life-expectancy, reduced general condition, comorbidities, and reduced…
- Trial name
- TIE (NCT00678964)
- Testing
- Erlotinib, Vinorelbine and Carboplatin
- Where
- 40 sites in Germany
- Volunteers
- 260 people
- Sponsor
- LungenClinic Grosshansdorf
Metastatic NSCLC, Metastatic Head and Neck Cancer
Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers
Immunotherapy is widely administrated as anticancer treatment in metastatic setting. Despite a proved efficacy in several cancer types and clinical situations, it exists a wide variability of responses in terms of efficacy and…
- Trial name
- MADMAS (NCT05091190)
- Testing
- Blood draws
- Where
- 2 sites in France
- Volunteers
- 75 people
- Sponsor
- Hospices Civils de Lyon